[This is a Rerelease. Episode first published on April 11, 2025.]

Listen to Dr. Jan Moritz Middeke from University Hospital in Dresden as he discusses the future of clinical trials in hematology and the role artificial intelligence (AI) may play in that field.

Dr. Middeke explains how synthetic data is generated and what are the potential benefits and limitations of its use in clinical trials. He also points out the open questions and hurdles that need to be addressed before AI-generated synthetic patients can be included in clinical trial design.

Tune in to hear how Dr. Middeke envisages the role of AI in solving the challenges of clinical trials for rare malignant diseases and how it may accelerate data generation and access to novel therapies.

If you want to know more:

⁠https://www.nature.com/articles/s41746-024-01076-x⁠ 

Host: Isabel Olivera-Martinez, PhD, Medical Writer 

Guest: Dr. Jan Moritz Middeke

Learn More

What did you think of this podcast? Share your opinions with us in this short feedback survey.

⁠https://forms.monday.com/forms/d02e52896815eef59ecae09fb74dd78f?r=use1⁠

Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.

⁠https://ehaedu.org/Campus⁠

Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.

Follow EHA on Instagram: ⁠https://www.instagram.com/EHA_Hematology/⁠

Facebook: ⁠https://e-h-a.link/facebook⁠

LinkedIn: ⁠https://www.linkedin.com/company/eha/⁠

Email us: [email protected]

Subscribe to receive the EHA Educational Updates via ⁠https://eha.news/subscribe⁠